Assessing heterogeneity in clinical trials using the frailty model - Legrand, Catherine
44,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

While the primary objective of multicenter clinical trials is to compare treatments for a specific disease, they also contain a lot of relevant additional information. For example, it may be interesting to investigate heterogeneity in outcome and in treatment effect over centers. Considering a frailty model including a random center effect and a random treatment by center interaction term, we demonstrate how to quantify this heterogeneity, to interpret it based on medically relevant quantities, and to identify center and patient specific factors explaining it. Based on the same idea, we also…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
While the primary objective of multicenter clinical trials is to compare treatments for a specific disease, they also contain a lot of relevant additional information. For example, it may be interesting to investigate heterogeneity in outcome and in treatment effect over centers. Considering a frailty model including a random center effect and a random treatment by center interaction term, we demonstrate how to quantify this heterogeneity, to interpret it based on medically relevant quantities, and to identify center and patient specific factors explaining it. Based on the same idea, we also propose to study heterogeneity in prognostic index effect over centers, and to use this information to get a new insight in the validation of prognostic indices. Various approaches are discussed to fit such a frailty model, and a Bayesian approach based on the Laplace approximation is detailled. We illustrate this research using data from an EORTC multicenter clinical trial for breast cancer and from a pooled database of seven EORTC clinical trials in bladder cancer patients.
Autorenporträt
Catherine Legrand holds a MSc in Mathematics (ULB, Belgium) and a PhD in Statistics (UHasselt, Belgium). She worked as biostatistician for the European Organization for Research and Treatment of Cancer (EORTC) and Merck Sharp & Dohme (MSD). She is now assistant professor at the Institute of Statistics of UCL (Louvain-la-Neuve, Belgium).